Glycaemic control and vascular complications in type 2 diabetes: new observations and clinical significance.
Whether intensive gylcaemic control can reduce the cardiovascular complications in type 2 diabetes has been answered in three clinical trials (ACCORD, ADVANCE and VADT). All three studies measured microvascular complications as well as macrovascular end points. It is important to initiate intensive glycaemic control early in the course of diabetes. Type 2 diabetes mellitus patients require lifestyle modification plus combinations of insulin sensitisers and insulin secretagogues. It target glycaemic control is not achieved then either incretin minetics or insulin can be added.
Lebovitz
Harold E
HE
State University of New York Health Science Center, Brooklyn, New York 11203, USA.
D000368:Aged; D015897:Comorbidity; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology / Q000517:prevention & control*; D003925:Diabetic Angiopathies / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D006943:Hyperglycemia / Q000453:epidemiology / Q000517:prevention & control*; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use; D016896:Treatment Outcome
D007004:Hypoglycemic Agents; D007328:Insulin; D045162:Thiazolidinediones; D000077154:Rosiglitazone